Glaukos Receives FDA Approval of Epioxa for the Treatment of Keratoconus

ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, has announced that the U.S. Food and Drug Administration (FDA) approved its Epioxa HD/Epioxa New Drug Application (NDA) for the treatment of keratoconus. Epioxa is an advancement in corneal cross-linking for keratoconus, a condition of the eye in which the normally rounded cornea bulges outward into a cone shape. Glaukos said it intends for Epioxa to be commercially available in the first quarter of 2026.